[Temporary Announcement] Northland: 2025 Annual Results Express Announcement
Securities code: 920047 Securities abbreviation: Northland Announcement number: 2026-008
Beijing Northland Biotechnology Co., Ltd.
2025 Annual Results Express Announcement
The company and all members of the board of directors guarantee that the contents of the announcement are true, accurate and complete and that there are no false records.
contains, misleading statements or major omissions, and is personally responsible for the authenticity, accuracy and completeness of its contents.
Notwithstanding joint and several legal liability.
Special reminder: The main financial data for 2025 contained in this announcement are preliminary accounting data and have not been reviewed.
audited by an accounting firm. The specific data shall be subject to the data disclosed in the company’s 2025 annual report. Investors are requested to
Investors should pay attention to investment risks.
1. Main financial data and indicators in 2025
Unit: Yuan
Item This reporting period The same period last year Change ratio % Operating income 66,449,532.59 72,110,862.43 -7.85% Total profit -53,706,119.86 -39,785,960.55 -Net profit attributable to shareholders of listed companies -53,722,574.18 -45,180,740.62 -Net profit attributable to shareholders of listed companies after deducting extraordinary gains and losses -55,643,975.27 -57,015,282.85
Basic earnings per share -0.20 -0.17 - Weighted average return on equity % (before deductions for non-exclusions) -17.64% -13.50% - Weighted average return on equity % (after deductions for non-exclusions) -18.27% -17.04% -
Item End of the reporting period Beginning of the reporting period Change ratio % Total assets 482,507,243.08 477,534,006.34 1.04% Owner’s equity attributable to shareholders of listed companies 277,674,665.03 331,442,284.06 -16.22% Equity 274,271,974.00 274,271,974.00 0.00% Net assets per share attributable to shareholders of listed companies 1.01 1.21 -16.53%
2. Description of operating performance and financial status
(1) Operating conditions, financial status and main factors affecting operating performance during the reporting period
During the reporting period, the company is expected to achieve operating income of 66,449,532.59 yuan, a year-on-year decrease of 7.85%; net profit attributable to shareholders of the listed company is -53,722,574.18 yuan; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses -55,643,975.27 yuan; basic earnings per share is -0.20 yuan.
At the end of the reporting period, the company's total assets are expected to be 482,507,243.08 yuan, a year-on-year increase of 1.04%; the owner's equity attributable to shareholders of the listed company is 277,674,665.03 yuan, a year-on-year decrease of 16.22%; the net assets per share attributable to shareholders of the listed company are 1.01 yuan, a year-on-year decrease of 16.53%.
(2) Main reasons for changes in performance
The company's new biological drugs are still in the research and development stage and have not yet been commercialized. Therefore, the net profit attributable to shareholders of the listed company during the reporting period is still negative; the net profit attributable to shareholders of the listed company is -53,722,574.18 yuan, an increase of 8,541,8 yuan compared with the same period last year. 33.56 yuan, mainly due to: (1) Affected by the business transformation of the company's major CMO customers, operating income decreased compared with the same period last year; (2) Other income decreased compared with the same period last year; (3) As the balance of monetary funds decreased, interest income decreased and financial expenses increased compared with the same period last year.
3. Risk warning
This performance report is the preliminary calculation data of the company's financial department, which has not been audited by the accounting firm and does not constitute the company's performance commitment to investors. The final data is subject to the data in the company's officially disclosed 2025 annual report. Investors are advised to make prudent decisions and pay attention to investment risks.
4. Document directory for reference
The balance sheet and income statement signed and sealed by the company's legal representative, the person in charge of accounting work, and the person in charge of the accounting department.
Board of Directors of Beijing Northland Biotechnology Co., Ltd.
February 26, 2026